ALK and non-small cell lung carcinoma: A recent phase III trial has reported that patients with ALK-p ALK-inhibitor-naïve advanced NSCLC (with and without CNS metastases) who had been treated with lorlatinib showed a prolonged PFS compared to those treated with crizotinib [33].